Switching Back to Mounjaro from Wegovy: What You Need to Know

You've tried Wegovy and you're wondering whether going back makes sense

It happens more than you might think. Someone switches from Mounjaro to Wegovy, perhaps because of supply issues, a change in prescription, or curiosity about how the two medicines compare, and then finds the results or tolerability aren't what they hoped. The question of switching back to Mounjaro from Wegovy is a sensible one, and there is no shame in asking it. Both medicines are licensed in the UK for weight management, and neither is a permanent commitment carved in stone.

The practical starting point: Mounjaro (tirzepatide) and Wegovy (semaglutide) work differently. Mounjaro activates two gut-hormone receptors, GIP and GLP-1, while Wegovy targets GLP-1 alone. That distinction matters when switching, because your body may respond differently to the reintroduction of a dual-agonist after a period on a single-pathway medicine. A prescriber needs to assess where you are in your current treatment, what dose you have reached, and how long you have been on Wegovy before advising on timing and the appropriate starting dose for any switch. The NHS tirzepatide medicines page covers the clinical basics of how the medicine works.

There is no fixed washout period published in the UK guidance specifically for switching between these two medicines. What exists is prescriber judgement, informed by your individual circumstances. That is exactly why this decision belongs in a consultation, not a forum thread.

What the evidence says when comparing Mounjaro and Wegovy side by side

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, is the most important piece of direct evidence here. It was an open-label head-to-head study in 751 adults with obesity and no diabetes, running for 72 weeks. Participants taking tirzepatide achieved greater average weight reduction than those taking semaglutide 2.4mg. NICE's appraisal of tirzepatide (TA1026) also notes that indirect comparisons across trials favour tirzepatide on weight outcomes. That said, the gap narrows with the newer Wegovy 7.2mg dose, and individual responses vary considerably.

The table below sets out the key factual differences between the two medicines as they stand in the UK.

These figures come from clinical trials under controlled conditions. Real-world results vary. The table is a reference point, not a verdict on which medicine is right for you, that is precisely what a prescriber's assessment is for. If you'd like a broader look at how these two medicines compare across cost, tolerability and access, our Wegovy vs Mounjaro comparison page covers more ground.

The dose question: where would you restart Mounjaro?

This is the part patients often find surprising. Switching back to Mounjaro does not automatically mean picking up where you left off. A prescriber may advise starting again at a lower dose, particularly if there has been a gap in treatment or if your previous experience included significant side effects at higher doses. The 2.5mg starting dose exists for a reason: it gives your system time to adjust before the dose climbs. Jumping straight back in at 10mg, say, after months on Wegovy, is not a decision to make unilaterally.

For patients considering the reverse journey, our guide to switching from Mounjaro to Wegovy is covered separately, it involves its own set of titration considerations. And if you have questions about whether switching between these two medicines is possible for your situation, that page works through the practical and clinical factors in plain terms. If you've come across questions about switching between semaglutide products more broadly, the position on Mounjaro and Ozempic is worth reading, because Ozempic is licensed for type 2 diabetes in the UK, not weight management, and conflating the two is a common and important error.

If you're looking at the price side of this, our Mounjaro vs Wegovy UK cost page sets out what private treatment typically costs for each, so you can factor that into your thinking before the consultation. A prescriber is not the right person to ask about price comparison, but they are exactly the right person to ask about clinical suitability.

How to make the switch safely, and what our prescribers look at

At nume, a switch between weight-loss medicines is treated as a fresh clinical assessment. Patients transferring from Wegovy to Mounjaro need to provide evidence of their current treatment and recent dosing history. A named prescriber, not software, reviews your answers and medical background the same day. If the switch is clinically appropriate, treatment can be dispatched before the end of the working day, most people find it straightforward to have the new pen arrive before their next scheduled dose would have been due, which keeps the rhythm of weekly treatment uninterrupted.

The step-by-step guide to switching back to Mounjaro walks through the process in more practical detail. You can also browse the weight-loss treatment overview for context on how each medicine fits the broader picture, or read about our clinical team if you'd like to understand who is reviewing your case. The FAQs page addresses common questions about transfers and repeat prescriptions.

Which medicine suits you best is a clinical decision made with our prescribers, not one that should be made by comparing trial statistics alone. Start your free consultation and a prescriber will review your situation the same day.